UPDATE: Smith & Nephew Shares Jump After J&J Offer Reports
January 10 2011 - 4:25AM
Dow Jones News
Shares in Smith & Nephew PLC (SN.LN) gained more than 12%
Monday following reports the U.K. medical device maker received and
rejected a bid approach from U.S. healthcare giant Johnson &
Johnson (JNJ) late last year, without informing shareholders.
Sky News reported on its website Saturday that Johnson &
Johnson approached Smith & Nephew in December with a proposal
pitched at 750 pence a share, valuing the company at roughly GBP7
billion. It didn't say where it got the information.
The Financial Times newspaper, citing unidentified people close
to Smith & Nephew, said the company rejected a 750 pence to 800
pence a share proposal as too low.
Spokesmen for Smith & Nephew and Johnson & Johnson could
not immediately be reached for comment.
At 0948 GMT, shares in Smith & Nephew were 79 pence or 12.1%
higher at 729 pence, making it the biggest riser in a lower FTSE
100, down 0.3%.
Smith & Nephew has been the subject of persistent takeover
speculation for years, with U.S. rivals in the market for
replacement hips and knees like Zimmer Holdings Inc. (ZMH) and
privately-held Biomet Inc. frequently touted as possible
suitors.
Johnson & Johnson also sells replacement joints through its
DePuy subsidiary.
Some analysts said an offer price of at least 900 pence per
share would be more realistic for the U.K. medical device
maker.
"To us, an offer above 900p would be a fairer price for a change
of control," said Panmure analyst Savvas Neophytou, while
reiterating a buy recommendation and 750 pence price target for the
stock.
Investec agreed. "Johnson & Johnson is a credible bidder,
has plenty of firepower and with other parties likely to be
interested, we think an offer of north of 900p is possible," the
broker said in a note while maintaining a buy rating and 703p
target price.
Analysts at UBS said any bid from J&J for Smith & Nephew
would likely attract the attention of antitrust authorities in the
U.S. and Europe, who may require the companies to sell assets to
clear the deal.
Analysts at Bernstein said an approach by Biomet's private
equity owners for Smith & Nephew is more plausible. Biomet
couldn't be reached for comment.
-By Jason Douglas, Dow Jones Newswires; 44-20-7842-9272;
jason.douglas@dowjones.com
(Sten Stovall contributed to this article.)
Biomet (NASDAQ:BMET)
Historical Stock Chart
From Apr 2024 to May 2024
Biomet (NASDAQ:BMET)
Historical Stock Chart
From May 2023 to May 2024